Briumvi (ublituximab-xiiy) is a CD20-directed cytolytic antibody used for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), active secondary progressive disease, and relapsing-remitting disease, in adults.
Recommended Dosage: The recommended dosage of Briumvi injection must be administered under the close supervision of an experienced clinician with access to relevant medical support to manage serious reactions, such as severe infusion reactions.
First Infusion: 150 mg intravenous (IV) infusion.
Second Infusion: 450 mg intravenous (IV) infusion administered 2 weeks following the first infusion.
Subsequent Infusions: 450 mg intravenous (IV) infusion administered 24 weeks following the first infusion and every 24 weeks thereafter.
In case a scheduled infusion is missed, administer it as promptly as possible; do not wait until the next planned infusion. Reset the Briumvi infusion schedule to administer the next sequential infusion 24 weeks after the skipped/missed infusion is administered. Infusions must be separated by at least five months.